(Q57159144)

English

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

scientific article published in The Lancet

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

based on heuristic

inferred from title

phase III clinical trial

1 reference

based on heuristic

inferred from title

José Luis López Estebaranz

0 references

Brian J Nickoloff

15

object named as

Brian J Nickoloff

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Anca Zbranca-Toporas

1 reference

ORCID Public Data File 2021

object named as

Kim Papp

16

1 reference

ORCID Public Data File 2021

George Sorin Tiplica

1 reference

ORCID Public Data File 2021

author name string

Christopher E M Griffiths

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Kristian Reich

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Mark Lebwohl

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Peter van de Kerkhof

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Carle Paul

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Alan Menter

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Gregory S Cameron

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Janelle Erickson

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lu Zhang

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Roberta J Secrest

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Susan Ball

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Daniel K Braun

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Olawale O Osuntokun

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Michael P Heffernan

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

UNCOVER-2 and UNCOVER-3 investigators

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

0 references

publication date

10 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

386

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

9993

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

541-551

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunology of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting IL-17 and TH17 cells in chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab in plaque psoriasis--results of two phase 3 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment goals in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

PASI90 response: the new standard in therapeutic efficacy for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960125-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)60125-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26072109%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57159144&oldid=1759857103"